Coloplast A/S

LSE:0QBO Stock Report

Market Cap: DKK 181.9b

Coloplast Valuation

Is 0QBO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QBO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
DKK 1.41k
Fair Value
42.8% undervalued intrinsic discount
22
Number of Analysts

Below Fair Value: 0QBO (DKK804.21) is trading below our estimate of fair value (DKK1405.56)

Significantly Below Fair Value: 0QBO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QBO?

Key metric: As 0QBO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QBO. This is calculated by dividing 0QBO's market cap by their current earnings.
What is 0QBO's PE Ratio?
PE Ratio36x
EarningsDKK 5.05b
Market CapDKK 181.91b

Price to Earnings Ratio vs Peers

How does 0QBO's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QBO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37x
CTEC ConvaTec Group
39.3x20.4%UK£4.9b
AMS Advanced Medical Solutions Group
43.2x20.8%UK£481.5m
TSTL Tristel
29.8x17.5%UK£193.2m
SN. Smith & Nephew
35.7x22.6%UK£8.9b
0QBO Coloplast
36x11.8%DKK 181.9b

Price-To-Earnings vs Peers: 0QBO is good value based on its Price-To-Earnings Ratio (36x) compared to the peer average (37x).

Price to Earnings Ratio vs Industry

How does 0QBO's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0QBO 36.0xIndustry Avg. 31.0xNo. of Companies9PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QBO is expensive based on its Price-To-Earnings Ratio (36x) compared to the European Medical Equipment industry average (31x).

Price to Earnings Ratio vs Fair Ratio

What is 0QBO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QBO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio36x
Fair PE Ratio37.8x

Price-To-Earnings vs Fair Ratio: 0QBO is good value based on its Price-To-Earnings Ratio (36x) compared to the estimated Fair Price-To-Earnings Ratio (37.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QBO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 804.21
DKK 905.68
+12.6%
11.3%DKK 1,030.00DKK 700.00n/a22
Jan ’26DKK 789.29
DKK 924.43
+17.1%
9.4%DKK 1,030.00DKK 700.00n/a21
Dec ’25DKK 889.40
DKK 924.67
+4.0%
9.4%DKK 1,030.00DKK 700.00n/a21
Nov ’25DKK 872.60
DKK 913.33
+4.7%
11.0%DKK 1,050.00DKK 700.00n/a21
Oct ’25DKK 879.49
DKK 913.60
+3.9%
11.0%DKK 1,060.00DKK 700.00n/a20
Sep ’25DKK 923.69
DKK 911.35
-1.3%
11.3%DKK 1,060.00DKK 700.00n/a20
Aug ’25DKK 898.15
DKK 905.90
+0.9%
11.0%DKK 1,060.00DKK 710.00n/a20
Jul ’25DKK 837.11
DKK 895.40
+7.0%
10.5%DKK 1,060.00DKK 710.00n/a20
Jun ’25DKK 818.86
DKK 909.89
+11.1%
10.2%DKK 1,060.00DKK 710.00n/a19
May ’25DKK 842.75
DKK 917.05
+8.8%
10.9%DKK 1,060.00DKK 700.00n/a19
Apr ’25DKK 929.56
DKK 897.32
-3.5%
10.3%DKK 1,060.00DKK 700.00n/a19
Mar ’25DKK 911.42
DKK 871.79
-4.3%
10.1%DKK 1,000.00DKK 700.00n/a19
Feb ’25DKK 799.42
DKK 823.74
+3.0%
9.8%DKK 962.00DKK 631.00n/a19
Jan ’25DKK 772.00
DKK 816.56
+5.8%
10.3%DKK 962.00DKK 631.00DKK 789.2918
Dec ’24DKK 795.52
DKK 817.67
+2.8%
10.1%DKK 962.00DKK 631.00DKK 889.4018
Nov ’24DKK 744.07
DKK 848.78
+14.1%
9.2%DKK 980.00DKK 686.00DKK 872.6018
Oct ’24DKK 747.60
DKK 865.24
+15.7%
9.9%DKK 1,000.00DKK 686.00DKK 879.4917
Sep ’24DKK 792.36
DKK 907.53
+14.5%
10.1%DKK 1,070.00DKK 720.00DKK 923.6915
Aug ’24DKK 827.11
DKK 928.88
+12.3%
9.9%DKK 1,070.00DKK 720.00DKK 898.1516
Jul ’24DKK 853.19
DKK 915.44
+7.3%
11.0%DKK 1,070.00DKK 690.00DKK 837.1116
Jun ’24DKK 873.87
DKK 915.44
+4.8%
11.0%DKK 1,070.00DKK 690.00DKK 818.8616
May ’24DKK 970.77
DKK 912.94
-6.0%
10.0%DKK 1,045.00DKK 690.00DKK 842.7516
Apr ’24DKK 901.80
DKK 902.63
+0.09%
9.8%DKK 1,045.00DKK 690.00DKK 929.5616
Mar ’24DKK 803.72
DKK 903.13
+12.4%
10.2%DKK 1,045.00DKK 690.00DKK 911.4215
Feb ’24DKK 838.42
DKK 907.33
+8.2%
9.7%DKK 1,045.00DKK 690.00DKK 799.4215
Jan ’24DKK 816.00
DKK 918.87
+12.6%
7.7%DKK 1,045.00DKK 798.00DKK 772.0015
Analyst Price Target
Consensus Narrative from 22 Analysts
DKK 901.43
Fair Value
10.8% undervalued intrinsic discount
22
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/19 19:57
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Coloplast A/S is covered by 48 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Robert BateBarclays
Hassan Al-WakeelBarclays